On August 31, 2026, the U.S. Food and Drug Administration (FDA) and the U.S. Securities and Exchange Commission (SEC) entered a Memorandum of Understanding (MOU) to enhance cooperation in their regulatory and enforcement responsibilities to improve market oversight and compliance.Continue reading
Author Archive: AZBio
BioLab Holdings Launches EmeraNova™ to Advance the Future of Tissue Restoration
Expanded vision reflects focus beyond wound care to advancing innovation across the full tissue restoration journey Continue reading
FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development Effort begins by Soliciting Public Feedback
The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases. As outlined in a new white paper, the Initiative will develop an optimized, fit-for-purpose framework that reflects the realities of rare disease drug development by considering the nuances of each disease, patient needs, product type and the evidence that can be realistically generated in small patient populations.
Continue reading
Tesoro VC announces Frontier Forum in partnership with the City of Phoenix
Global startups advancing AI chips, robotics, quantum computing, biotechnology, dual-use and defense technologies to join a planned gathering of 300 founders, investors and industry leaders in PhoenixContinue reading
Study identifies protein signature that could help detect advanced fibrosis in liver disease
Extracellular vesicles offer a more precise window into liver injury than traditional blood testsContinue reading
TGen, Mayo study offers glimpse at early sepsis stages in the brain
Study shows how vascular system is first to break down, along with inflammatory responseContinue reading
BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.
Continue reading
ACES Diagnostics Research Demonstrates Potential of LymeSeek™ to Improve Detection of Early Lyme Disease
Peer-reviewed study in the Journal of Clinical Microbiology reports more than 90% sensitivity across disease stages and improved detection during the early diagnostic “gray zone.” Continue reading
TGen led study lays groundwork for using cell-free DNA to monitor glioblastoma
Method could someday be used to assess treatment responseContinue reading
Vitalant Launches Cell-Based Analytics Lab to Support Allogeneic Therapy Developers
- New Phoenix laboratory expands Vitalant’s CGT analytics network with additional donor characterization and immune profiling capabilities
- Orthogonal cell-based analytics platforms will support assay development and immunomodulatory product development